Skip to content

Supernus Pharmaceuticals

US · SUPN #2636 by market cap Listed 1970
28.61 +0.26 +0.92%
Periodic snapshot; not a real-time feed. · 2026-11-20 16:48

Recent news

  • Rating change
    Cantor Fitzgerald Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Raises Target Price to $67
    Market Newswire · 2026/7/9
  • Rating change
    Piper Sandler Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Raises Target Price to $66
    Market Newswire · 2026/4/13
  • Rating change
    Cantor Fitzgerald Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $63
    Market Newswire · 2026/1/9
  • Piper Sandler Maintains Supernus(SUPN.US) With Buy Rating, Cuts Target Price to $47
    Market Newswire · 2026/11/5
  • Rating change
    Piper Sandler Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $66
    Market Newswire · 2026/7/27
  • Stifel Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Maintains Target Price $55
    Market Newswire · 2026/10/31
  • Company notice
    Supernus Pharmaceuticals: Supernus Pharmaceuticals, Inc. - Anticipated Adjustment Option Symbol: SUPN New Symbol: SUPN1
    OCC · 2026/9/17
  • Stifel Maintains Supernus(SUPN.US) With Hold Rating, Cuts Target Price to $37
    Market Newswire · 2026/11/5
  • Rating change
    TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Raises Target Price to $65
    Market Newswire · 2026/2/25
  • Company notice
    Supernus: Supernus Pharmaceuticals, Inc. - Contract Adjustment Option Symbol: 11/02/2026 - SUPN Remains SUPN 11/03/2026 - SUPN Becomes SUPN1
    OCC · 2026/11/2
  • Rating change
    TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $60
    Market Newswire · 2025/11/5
  • Company notice
    Supernus: Supernus Pharmaceuticals, Inc. - Contract Adjustment Option Symbol: 11/02/2026 - SUPN Remains SUPN 11/03/2026 - SUPN Becomes SUPN1 * * * Update * * *
    OCC · 2026/11/3
  • Rating change
    Piper Sandler Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $65
    Market Newswire · 2026/1/28
  • Company notice
    Indivior: Indivior Pharmaceuticals, Inc. - Cash Distribution and Name/Symbol Change Option Symbol: INDV New Symbol: SUPN
    OCC · 2026/11/3
  • Rating change
    TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $65
    Market Newswire · 2026/10/21
  • Rating change
    BofA Securities Initiates Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Announces Target Price $63
    Market Newswire · 2026/7/13
  • News On Indivior Pharmaceuticals Inc. (INDV) Now Under SUPN
    Dow Jones · 2026/11/4
  • Rating change
    BofA Securities Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $65
    Market Newswire · 2026/2/25
  • Cantor Fitzgerald Maintains Supernus(SUPN.US) With Buy Rating, Raises Target Price to $87
    Market Newswire · 2026/11/5
  • Rating change
    Stifel Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Raises Target Price to $55
    Market Newswire · 2025/12/19
  • Rating change
    Cantor Fitzgerald Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Raises Target Price to $63
    Market Newswire · 2025/9/30
  • Earnings Flash (SUPN) Supernus Pharmaceuticals Posts Q2 Net Loss $1.01 a Share, Vs. FactSet Est of $0.04 EPS
    MT Newswires · 2026/8/3
  • Rating change
    Piper Sandler Upgrades Supernus Pharmaceuticals(SUPN.US) to Buy Rating, Raises Target Price to $65
    Market Newswire · 2025/10/9
  • Rating change
    Stifel Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Raises Target Price to $43
    Market Newswire · 2025/8/7
  • Rating change
    Cantor Fitzgerald Upgrades Supernus Pharmaceuticals(SUPN.US) to Buy Rating, Raises Target Price to $42
    Market Newswire · 2025/7/30

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 16:48:01 · For reference only, not investment advice and not tailored to your situation.

Supernus Pharmaceuticals discussion 0 comments

Add a comment